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).a b s t r a c t
A novel phototheranostic platform based on tri-malonate derivative of fullerene C70 (TFC70)/photosen-
sitizer (Chlorin e6, Ce6) nanovesicles (FCNVs) has been developed for effective tumor imaging and
treatment. The FCNVs were prepared from amphiphilic TFC70-oligo ethylene glycol -Ce6 molecules. The
developed FCNVs possessed the following advantages: (i) high loading efﬁciency of Ce6 (up to ~57 wt%);
(ii) efﬁcient absorption in near-infrared light region; (iii) enhanced cellular uptake efﬁciency of Ce6
in vitro and in vivo; (iv) good biocompatibility and total clearance out from the body. These unique
properties suggest that the as-prepared FCNVs could be applied as an ideal theranostic agent for
simultaneous imaging and photodynamic therapy of tumor. This ﬁnding may provide a good solution to
highly efﬁcient phototheranostic applications based on fullerene derivatives fabricated nanostructures.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Phototheranostics, which refers to diagnosis via application of
light with simultaneous treatment of disease, has emerged as a
promising interdisciplinary technique for imaging guided tumor
treatment due to improvement in light generation, delivery, and
sensing technologies [1e5]. Among phototheranostics, photody-
namic therapy (PDT) based theranostics as an alternative tumor-
ablative method has unique advantage in comparison with the
conventional methods (i.e. surgery, chemotherapy and radio-
therapy) since it is a less invasive and more controllable technique,
which has been approved by Food and Drug Administration for
treatment of various non-malignancies and malignancies [6,7]. In
PDT, photosensitizer (PS) as a key component could transfer the, shucy@iccas.ac.cn (C. Shu).
r Ltd. This is an open access articleenergy of light to surrounding oxygen [8e10], producing reactive
oxygen species (ROS) to induce irreversible damage of cancer cells
and achieve an effective tumor ablation [11e13]. Chlorin e6 (Ce6) as
a most commonly used PS, has stronger absorption in near-infrared
(NIR) light region and higher singlet oxygen (1O2) quantum yield
because of its large p-conjugated aromatic domains [14,15].
Moreover, Ce6 could be further used as a NIR ﬂuorescence (FL)
imaging agent in the spectral range of 650e800 nm to avoid the
interference of endogenous chromophores within the body [16].
However, Ce6 is highly insoluble in water and tends to form ag-
gregates, as a result, reducing its PDT efﬁciency due to the p-p
interactions [17]. Moreover, Ce6 as a small molecule usually ex-
hibits non-speciﬁc delivery and non-ideal biodistribution proper-
ties and therefore hardly meets the requirement of real-time tumor
treatment [18].
As smart carbonaceous nanomaterials, fullerene derivatives
have been reported as PSs for PDT due to their good biocompati-
bility, facile multiple surface functionalization, and efﬁcientunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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Most importantly, fullerene derivatives could be totally cleared out
from the body according to the reports in literature [24e26]. Un-
fortunately, the UV-to-Vis excitation of fullerene derivatives hin-
ders the enhancement of PDT efﬁciency in vivo due to the limited
penetration depth of UV-to-Vis irradiation [27e32].
The application of self-assembled nanomaterials for PDT has the
potential to overcome these aforementioned limitations of Ce6 and
fullerene derivatives by enabling the engineered nanostructures to
navigate in vivo in speciﬁc ways and enhancing the NIR light ab-
sorption of fullerene [33,34]. As we know, amphiphilic molecule is
widely used to self-assemble into nanovesicles through the
controlled balance between hydrophilic parts and hydrophobic
parts [35e37]. The formed nanovesicles have attracted consider-
able attention due to their hollow structures similar to the organ-
elles in cells as well as their emerging collective properties arising
from coupling between nanoparticles within assemblies [38e43].
Currently, numerous amphiphilic materials such as chitosan,
polymer, liposome, protein, and gold nanoparticles, have been re-
ported to self-assemble into vesicles for drug delivery and cancer
therapy [44e51]. However, so far there is no report about the
nanovesicles based on amphiphilic fullerene derivatives for pho-
totheranostics application. Therefore, it is of great interest to
develop nanovesicles based on fullerene derivatives/PS and explore
their cancer therapy efﬁciency as novel phototheranostic agents.
Herein, we report a new phototheranostic platform based on tri-
malonate derivative of fullerene (TFC70)/PS (Ce6) nanovesicles
(FCNVs), and 1,10-Diamino-4,7-dioxadecane (OEG2) as a linker, as
shown in Scheme 1. Amphiphilic TFC70-OEG2-Ce6 molecule was
prepared via coupling reaction between amine groups on OEG2
modiﬁed Ce6 and carboxylic groups on TFC70 in water/DMSO
mixture solution. We then dialyzed the as-prepared amphiphilic
molecules to form the water-dispersible FCNVs. The obtained
water-dispersible and biocompatible FCNVs, not only could carry a
large amount of Ce6 to tumour site for imaging-guided and NIR
light-triggered PDT treatment, but also could excrete from body
after PDT. As far as we know, this study is the ﬁrst to demonstrate
the preparation of FCNVs as phototheranostics for imaging-guided
efﬁcient PDT in vivo, which may provide a new strategy for efﬁcient
phototheranostic applications based on fullerene derivatives
fabricated nanostructures.Scheme 1. Schematic fabrication of FCNVs as phototheranostic agent for PDT.2. Experimental section
2.1. Materials
Chlorin e6 was purchased from Innochem. 1,8-Diamino-3,6-
dioxaoctane, 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hy-
drochloride (EDC), N-Hydroxysuccinimide (NHS), Di-tert-butyl
pyrocarbonate ((Boc)2O), 1,8-diazobicyclo[5,40]undec-7-ene (DBU)
and triﬂuoroacetic acid (TFA) were purchased from Acros. The
culture medium Dulbecco's modiﬁed Eagle's medium (DMEM)
(Invitrogen, USA) supplemented with 10% fetal bovine serum (FBS,
Hyclone Company, South Logan, UT), penicillin (100 mg mL1), and
streptomycin (100 mg mL1) (Gibco, Grand Island, N. Y. USA), Cell
counting Kit-8 (CCK-8; DOJINDO, Kumamoto, Japan), Dil, MitoRed,
Lyso, PI and Hoechst 33258 were purchased from PuJingKangLi. All
other chemicals used were analytical reagents.
2.2. Characterization
1H NMR spectroscopy was recorded on Bruker Advance
400 MHz NMR spectrometer at 25 C. Matrix-assisted laser
desorption/ionization time of ﬂight mass spectra (MALDI-TOF MS)
were measured though AXIMA Assurance MALDI-TOF system. The
particle sizes and Zeta potentials were determined by dynamic
light scattering (DLS) using Malvern Nano-ZS90 apparatus (Mal-
vern Instruments). Scanning electron microscopy (SEM) was car-
ried out on a JEOL JSM-6701F electron microscope, Transmission
electronmicroscopy (TEM) was carried out on JEOL-JEM 2100F field
emission transmission electron microscope at 200 kV, and Atomic
force microscopy (AFM) was carried on MultiMode 8 (Bruker) were
used to characterize the morphology of FCNVs. Absorbance mea-
surements were carried out using UV2550 spectrophotometer
(SHIMADZU). FL spectra were acquired though Fluorolog spectro-
photometer. Fourier transform infrared spectroscopy (FTIR) spectra
weremeasured using Thermo instrument (NICOLET IN10MX). Flow
cytometric analysis was performed on ﬂow cytometer (ACCURIC6).
Cell viability was detected by 96-well plate reader (iMarkmicro-
plate reader, Bio-RAD, USA).
2.3. Synthesis of Boc-OEG2
The OEG2 (1 equiv.) in dichloromethane (DCM) solution was
treated with Boc2O (0.15 equiv.) in default for 5 h at 0 C and then
stirred at room temperature for 18 h. The organic phase was
washed with water until all the unreacted OEG2 was extracted. The
Boc-protected OEG2 was evaporated under vacuum after drying
with MgSO4. 1H NMR spectroscopy was used to conﬁrm the
structure of Boc-OEG2 (Fig. S1y). 1H NMR (400 MHz, CDCl3, 298 K)
d ¼ 5.26 (s, 1H, NHBoc), 3.51e3.44 (m, 4H, 2  glycol CH2),
3.43e3.39 (m, 4H, 2  glycol CH2), 3.20e3.18 (m, 2H, CH2NHBoc),
2.78e2.75 (t, J ¼ 5.6 Hz, 2H, CH2NH2), 1.87 (broad s, 2H, NH2), 1.33
(s, 9H, CH3).
2.4. Synthesis of Ce6-OEG2-Boc
100.0 mg (0.167 mmoL) of Ce6 was dissolved in 30 mL of DMSO.
58.0 mg (0.30mmoL) of EDC and 26.5 mg (0.23mmoL) of NHSwere
added into the above solution and stirred at room temperature for
1 h. Then 33.3 mg (0.13 mmoL) of Boc-OEG2 in 10 mL of DMSO was
added to above solution following by vigorously stirring for 24 h.
After that, the crude products were washed with water to remove
excess NHS and EDC. Then crude products were separated and
puriﬁed by silica gel chromatography with DCM: EtOH (v:v ¼ 9:1)
to afford Ce6-OEG2-Boc as conﬁrmed by MALDI-TOF-MS (Fig. S2y).
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TFA (25%) in DCM was added to Ce6-OEG2-Boc, which was
stirred at 0 C for 2 h to remove the tert-butyl group. After that,
solvent was evaporated under vacuum and the crude product was
dissolved in ethyl acetate. The pH of solution was adjusted to 8e9
by 5% sodium carbonate. Then solvent was evaporated and the
product was conﬁrmed by MALDI-TOF-MS (Fig. S3y).
2.6. Synthesis of tri-malonic acid modiﬁed fullerene (TFC70)
Malonic acid fullerene derivative was prepared according to our
previously reported [52]. Brieﬂy, C70 was converted into fullerene
malonic ester by treatment with diethyl bromomalonate and DBU
in dry toluene under nitrogen. The tri-malonate derivative of
fullerene was separated by silica gel column chromatography and
characterized by MALDI-TOF-MS. Hydrolysis of the purified
malonic acid fullerene derivative with NaH and CH3OH led to the
formation of the corresponding acid (TFC70).
2.7. Synthesis of FCNVs
TFC70 (21.8 mg, 0.02 mmoL) was dissolved in water (30 mL).
44.0 mg (0.23 mmoL) of EDC and 20.0 mg (0.17 mmoL) of NHS were
added into the above solution and stirred at room temperature for
1 h. Then 100.0mg (0.12mmoL) of Ce6-OEG2 in 10mL of DMSOwas
added to above solution following by vigorously stirring for 24 h.
The crude product was dialyzed against water for one week and
characterized by MALDI-TOF-MS (Fig. S4y), FTIR (Fig. S5y), SEM &
TEM (Fig. 1), UVeVis spectrophotometry and DLS (Fig. 2).
2.8. Density functional theory (DFT) calculations
DFT calculations were preformed to estimate the molecular
length by using the Dmol [3] code, all the calculations are repre-
sented at the double-numeric quality basis set with double nu-
merical plus polarization (DNP) functions level, which are
comparable to Gaussian 6-31G** sets. The exchange correlation
interactions are described by the PerdeweBurkeeErnzerhof
generalized gradient approximation (GGA). All atomic positions are
fully relaxed at the GGA level without symmetry restriction until
the atomic forces are smaller than 105 Hartree.
2.9. Ce6 loading efﬁciency measurements
To estimate the loading efﬁciency of Ce6 on TFC70, FCNVs
powder was collected by vacuum drying which was quantiﬁed by
using UV calibration curve of Ce6 at 403 nm. And the conjugated
Ce6 amount could be calculated by the equation: Ce6 loading
efﬁciency ¼ (weight of Ce6)/(weight of Ce6 þ weight of TFC70).
Every experiment was repeated three times. In the calibration
curve, the absorption intensity of 403 nm is linearly proportional to
the concentration of Ce6, following a regression equation:
Y ¼ 0.0132 þ 1.1846X (R2 ¼ 0.9997). This is reasonably consistent
with the MALDI-TOF MS of FCNVs (Fig. S4y).
2.10. In vitro cytotoxicity of FCNVs
The cytotoxicity of A549 cells toward FCNVs in vitrowas carried
out. A549 cells were seeded in a 96-well plate with a density of ca.
5  104 per well and cultured in 5% CO2 at 37 C for 24 h. A549 cells
were then treated with a series of gradient concentration of FCNVs
for 3 h in the dark and then irradiated with a 660 nm laser for
10 min (20 mW cm2). A549 cells only treated with FCNVs in the
dark for 24 h were used as a control. Then the culture mediumwasreplaced and the cells were cultivated for another 24 h in the dark
at 37 C. Cytotoxicity was evaluated by using a WST-8 assay with
CCK-8 which has characteristic absorbance at 450 nm. This can be
read with a 96-well plate reader to determine the cell viability.
A549 cells treated with either FCNVs (0.2 mg mL1), or TFC70
(0.1 mg mL1), and Ce6 (0.1 mg mL1) respectively, and blank cells
were used as controls. Both the Ce6 effective concentration of
FCNVs and Ce6 alone are 0.1 mgmL1. Then the cell viabilities were
detected by using CCK-8. Results are expressed as means ± SD.
2.11. Confocal images of treated A549 cells after stained with
Hoechst 33258, PI, Dil, MitoRed and LysoBlue
A549 cells were incubated with FCNVs (0.2 mg mL1) at 37 C,
5% CO2 for 3 h, then the aged cell culture was replaced with fresh
DMEM (without phenol red), the cells were exposed to an external
660 nm (20 mW cm2) laser for 10 min. After that either Hoechst
33258 (1 mg mL1, 5 mL, incubated with cell for 20 min), or PI
(1 mg mL1, 5 mL, incubated with cell for 15 min), Dil (1 mg mL1,
5 mL, incubated with cell for 20 min), MitoRed (1 mg mL1, 5 mL,
incubated with cell for 30 min) and Lyso (1 mg mL1, 5 mL, incu-
bated with cell for 45 min) were added respectively according to
the actual conditions and washed with icy PBS buffer for three
times before observation. The images were obtained by FV 1000-
IX81 confocal laser scanning microscope (Olympus, Japan). The
cells dyed under the same conditions without laser irradiationwere
used as controls.
2.12. Animal experiments
Female Balb/c mice (16e20 g) were purchased from Center for
Experimental Animals, Institute of Process Engineering, Chinese
Academy of Science (Beijing, China). In vivo study conforms to the
guidelines of the National Regulation of China for Care and Use of
Laboratory Animals. The tumor model was established by subcu-
taneous injection of 4T1-luc cells in the right buttock of each
mouse. The tumors were allowed to grow for 5 days to reach the
size of around ca. 50e100 mm3.
2.13. In vivo ﬂuorescence imaging (FL)
FL imaging was performed on an in vivo imaging system (CRI
Maestro 2) with a 660 nm laser as the light source. The FL imaging
were collected at 560e800 nm and analyzed with Maestro2 soft-
ware. The Balb/c mice were anesthetized with 1.5% pentobarbital
sodium by intraperitoneal injection at a dose of 120 mL. FCNVs
(1 mg mL1, 200 mL) were injected by intravenous injection and the
FL imaging was performed at timed intervals (0, 1, 4, 24 and 48 h).
Ce6 (0.5 mg mL1, 200 mL) was injected as control group. Both the
Ce6 effective concentration of FCNVs and Ce6 alone are
0.5 mg mL1.
2.14. In vivo toxicity studies
The tumor-bearing mice were randomized into four groups
(n ¼ 5, each group). Group 1 was treated by intravenous injection
with FCNVs at a dose of 200 mL (1 mg mL1), after 4 h post-
injection, tumor site was irradiated with 660 nm laser for 10 min
(100 mW cm2). Group 2 was treated with saline (200 mL) and
irradiated with 660 nm laser for 10 min (100 mW cm2). Another
two groups treated with either FCNVs (1 mgmL1, 200 mL) or saline
(200 mL) only without laser irradiation were also used as controls.
All the groups were received only once injection. The body weights
and tumor volumes were monitored every two days after treat-
ment. The tumor volume was calculated using the following
Fig. 1. (a) Illustration of the synthesis of FCNVs; (b) SEM image of FCNVs; (c) TEM image of FCNVs; (d) Optimized structure of TFC70/Ce6-OEG2 at the GGA-PBE/DNP theoretical level
by the DFT; (e) AFM image of FCNVs and the height of FCNVs is ca. 32 nm.
M. Guan et al. / Biomaterials 103 (2016) 75e8578equation: tumor volume (V) ¼ lengthwidth [2]/2. Relative tumor
volume was calculated as V/V0 (V0 is the corresponding tumor
volume when the treatment was initiated).
2.15. 131I labeling of FCNVs
Na131I was obtained from Peking University, FCNVs were labeled
by 131I using a standard chloramine T oxidation method [53]. A
mixture of 2 mL of FCNVs (2 mg mL1), 2.0 MBq Na131I and 100 mL
chloramine-T (10 mgmL1, Sigma-Aldrich) were reacted in a pH 7.5
phosphate buffer (0.02 M) for 2 h at room temperature. Excess 131I
was separated by silica gel column chromatography, and then
washed by centrifugal ﬁltration through Amicon ﬁlters
(MWCO ¼ 3 kDa) and washed with water 4e6 times until no
gamma activity was detected in the ﬁltrate solution. A radiolabeling
yield of 46% (purity 97%) was achieved.
2.16. Biodistribution
Female Balb/c mice (Harlan, USA) were injected with the solu-
tion of 131I-FCNVs in saline (6e7 mCi, 200 mL) via the tail vein. The
body weight of the animals used in this study averaged ca. 20 g. Themice were sacriﬁced and blood samples and major organs were
collected at assigned time points after injection (1 h, 4 h, 24 h, 2 d,
7 d, 15 d, and 20 d; n ¼ 5 per time point). The radioactivity of each
sample was measured by gamma counting. The percent of injected
dose per gram (%ID per g) of tissues was calculated from gamma
counting.
2.17. Bioluminescence imaging in vivo
Bioluminescence imaging was performed with a CALIPER
Lumina II in vivo imaging system (IVIS). A 680-sp ﬁlter was
employed as the emission ﬁlter for in vivo imaging tests and the
exposure time is 0.3 s. The tumor-bearing Balb/c mice were anes-
thetized with 1.5% pentobarbital sodium by intraperitoneal injec-
tion at a dose of 120 mL. D-Luciferin potassium (15mgmL1, 200 mL)
was injected by intraperitoneal injection and the bioluminescence
imaging was performed before and after PDT treatment for 15 days.
2.18. Histopathological examination
The major tissues (heart, liver, spleen, kidneys, and lung) were
harvested and ﬁxed in a 4% formalin solution. The histopathological
Fig. 2. (a) UVeVis absorption spectra of FCNVs (0.65 mg mL1, in water), Ce6 (0.30 mg mL1, in DMSO) and TFC70 (0.29 mg mL1, in water). Both the concentrations of Ce6 in FCNVs
and pristine Ce6 are 0.30 mg mL1, and both of the concentrations of TFC70 in FCNVs and pristine TFC70 are 0.29 mg mL1. Inset is photographs of Ce6, TFC70 and FCNVs aqueous
solution; (b) FL spectra of FCNVs (in water) and Ce6 (in water). Both the concentrations of Ce6 in FCNVs and pristine Ce6 are 0.1 mg mL1; (c) The relative UVeVis absorption of
FCNVs and Ce6 exposed to light irradiation for 10, 40, 70, 100, 130, 160 min, respectively, at a power density of 50 mW cm2; (d) Size distribution of FCNVs measured in water.
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Tissue samples were numbered and given blind to the pathologist
for conventional processing and analysis. Brieﬂy, the tissue samples
were embedded in parafﬁn blocks, sectioned into 4 mm slices, and
mounted onto the glass slides. After hematoxylin eosin (H&E)
staining, the sections were observed, and photographs were taken
using an optical microscope.
2.19. Statistical analysis
The statistical analysis of the samples was conducted by Stu-
dent's t-test, p < 0.01 were very significant (**). All data reported
are means ± standard deviations, unless otherwise noted.
3. Results and discussion
3.1. Preparation and characterization of FCNVs
In order to facilitate the successful coupling of Ce6 and TFC70,
OEG2 was introduced to Ce6, as shown in Fig. 1a (step 1) [54]. The
chemical structure of Boc-OEG2 was conﬁrmed by 1H NMR [55]
(Fig. S1y). Then, Ce6 was covalently linked with Boc-OEG2, the
molecular weight of obtained Ce6-OEG2-Boc was measured by
MALDI-TOF MS to be 826 (Fig. S2y), which is consistent with its
theoretical value. Finally, TFA was used to remove Boc-group, Ce6-
OEG2 with molecular weight of 726 (Fig. S3y) was obtained. The
involvement of smart OEG2 linkers facilitates the coupling reaction
of Ce6 and TFC70. The OEG2 linker prevents the direct interaction
between Ce6 and TFC70, preserving the ﬂuorescence of Ce6 to some
extent. Furthermore, the smart OEG2 also could minimize the
nonspeciﬁc interaction between obtained FCNVs and biological
molecules [54,56].
The FCNVs were prepared as illustrated in Fig. 1a (Steps 2e3). Instep 2, fullerene (C70) was initially modiﬁed with malonic acid as
TFC70, according to the previously reported [52]. In brief, C70 was
converted into fullerene malonic ester following treatment with
diethyl bromomalonate in dry toluene under nitrogen. The tri-
malonate derivative of C70 was separated by silica gel column
chromatography. Hydrolysis of the purified products with NaH and
CH3OH led to the formation of TFC70. After that, in step 3, TFC70 was
covalently linked with Ce6-OEG2 in water/DMSO mixture solution
(v/v, 4:1) to obtain Ce6-OEG2/TFC70. The obtained Ce6-OEG2/TFC70
was measured in methanol by MALDI-TOF MS to be 2576
(2526 þ 14) and 2590 (2526 þ 28) (Fig. S4y), which exceeded its
theoretical value (2526) by one or two methylene, due to the
involvement of methanol. The FTIR spectra in Fig. S5y exhibited
characteristic vibration of amide bond at 3370 cm1, 1645 cm1,
and 1400 cm1, indicating the successful preparation of amphi-
philic molecule, TFC70/Ce6-OEG2, in which TFC70-OEG2 acts as
hydrophilic part and Ce6 as hydrophobic part. The amphiphilic
properties enable TFC70/Ce6-OEG2 self-assemble into vesicular
structures through balance between two competing interactions
during the dialysis process in water [57e59].
SEM image (Fig. 1b) reveals that the morphology of the resulting
FCNVs is spherical with an average size of ca. 31 nm. TEM image in
Fig. 1c suggests that the individual FCNVs are hollow spheres with
shell thickness of ca. 9 nm. For better understanding of the resulting
structure, the molecular length of TFC70/Ce6-OEG2 is optimized at
the GGA-PBE/DNP theoretical level by the DFT [60] to be ca.
3.81 nm (Fig. 1d), which is approximately half that of the shell
thickness of FCNVs, suggesting that bilayer nanovesicles are
formed. The height of the FCNVs measured from AFM is about
32 nm (Fig. 1e), which is in a well agreement with SEM/TEM results
and further conﬁrms the formation of nanovesicles, whereas the
height of TFC70 in AFM image is about 2 nm (Fig. S6y).
The UVeVis spectra illustrate that FCNVs exhibit a stronger
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assembled structure can enhance the absorption (Fig. 2a). The FL
emission spectra of Ce6 and FCNVs exhibit the similar emissive
peak around 660 nm, as shown in Fig. 2b, the FL intensity of FCNVs
in aqueous solution is higher than that of free Ce6 due to the poor
solubility of Ce6 in water [61]. To investigate the interactions be-
tween TFC70 and Ce6, the FL emission spectra of Ce6, TFC70/Ce6-
OEG2, and FCNVs in water-DMSO mixture solution (v/v, 95/5)
were further investigated. As shown in Fig. S7y, partial FL emission
of Ce6 is quenched in both FCNVs and TFC70/Ce6-OEG2, due to the
partial close proximity of Ce6 to TFC70. The FL intensity of FCNVs is
lower than that of TFC70/Ce6-OEG2 which may ascribe to the p-p
stacking interaction between Ce6 molecules in FCNVs, similar to
the previous studies on the Ce6 based nanostructures for PDT
[16,62].
The time-dependent photostability of FCNVs was investigated
under an irradiation of 660 nm (50 mW cm2). As shown in Fig. 2c,
the absorbance intensity of FCNVs decreases slowly while that of
Ce6 decreases rapidly, indicating FCNVs possess improved photo-
stability. This phenomenon may ascribe to the energy transfer be-
tween C70 and Ce6, which result in the unique physical and
chemical properties of Ce6 [16,62]. FCNVs are stable in FBS as
shown in Fig. S8y, which would facilitate its biomedical application.
The DLS investigation shows that the diameters of FCNVs are ca.
65 nm in aqueous solution (Fig. 2d), ca. 103 nm in FBS and ca.
120 nm in PBS, respectively (Fig. S9y). This obvious difference
should ascribe to the different media. As literature reported, serum
proteins once associated with negative and positive charged
nanoparticles would form protein corona, leading to the increase of
size of nanoparticles in FBS [63]. Furthermore, the increased size of
FCNVs in PBS should beneﬁt from the change of surface potential
[13,64]. This size distribution could enable FCNVs to speciﬁcally
accumulate in tumour site through enhanced permeability and
retention (EPR) effect [65]. The Zeta potential of FCNVs is approx-
imately e 25.6 mV in water, indicating the surface of FCNVs is
negative charged (Fig. S10y). Ce6 loading efﬁciency on TFC70 could
be quantiﬁed by using the UVeVis calibration curve of Ce6 at
403 nm (Fig. S11y) [16]. Notably, the maximum loading efﬁciency
can reach to ~57 wt%, which is much higher than those previously
reports where Ce6 was loaded through either encapsulation or p-p
interaction (Table 1) [14,16,54,66e69]. This is further conﬁrmed by
MALDI-TOF MS (Fig. S4y).3.2. In vitro imaging and PDT
To investigate PDT effect of FCNVs, the capability of cell uptake
was initially studied. A549 cells were incubated with either FCNVs
or free Ce6 (at an equiv. Ce6 dose of 0.1 mg mL1) for 0.5, 1, 3, 7 and
24 h at 37 C and then imaged by a confocal FL microscope. As
shown in Fig. 3a, although the intracellular FL increased over time
for both Ce6 and FCNVs incubated cells, the latter showed much
stronger FL. Furthermore, quantitative evaluation of the cellularTable 1
Loading efﬁciency of Ce6 with different nanomaterials.
Nanocarriers Drug loading efﬁciency (wt%)
FCNVs 57
Iron oxide nanoclusters 6.514
Gold nanoparticles 18.416
Fullerene (C60) derivatives 23e2654
Silica-coated-gold nanoclusters 14.666
Graphene oxide 1567
Upconversion nanoparticles 6e868
MoS2 nanosheets 3069uptake toward Ce6 and FCNVs was carried out by comparing the FL
intensities of cellular lysates at different incubation time (0.5, 1, 3, 7
and 24 h). As revealed by Fig. 3b, the FL of FCNVs treated cells is
much higher than that of free Ce6, indicating the enhanced cellular
uptake of FCNVs, due to their good water-dispersibility and vesic-
ular structure, which is similar with previous report [70]. To vali-
date the concomitant generation of ROS induced by FCNVs under
660 laser irradiation, 20,70-dichloroﬂuorescein diacetate (DCFDA)
[71], a standard FL indicator for ROS was initially used to stain
A549 cells. As shown in Fig. 3c and d, the cells exposed to FCNVs
and Ce6 show intensifying FL of DCFDA over irradiation time,
clearly indicating the production of ROS. Notably, FL of DCFDA from
FCNVs treated cells is much higher than that of free Ce6, whereas
cells treated with DCFDA alone exhibit negligible FL, indicating the
enhanced ROS generation of FCNVs [72]. Free radical species
detection was subsequently carried out to identify which kind of
ROS was produced by FCNVs upon laser irradiation with different
ROS scavengers [20]. A549 cells were incubated with FCNVs
(0.2 mg mL1) in the dark for 3 h ﬁrst, and then the medium was
replaced by DMEM without phenol red, containing either 10 mM
sodium azide (NaN3), mannitol, or SOD (50 units). Subsequently,
the cells were irradiated at 660 nm laser for 10 min. From the re-
sults shown in Fig. S12y, we found that FCNVs alone efficiently
produced photo-damage toward cells while the 1O2 quencher
(NaN3) intensively blocked the FCNVs-induced cell death. In
contrast, the added free radical inhibitors (mannitol and SOD) did
not protect cells from FCNVs-induced photo-damage. The results
clearly demonstrate that FCNVs-induced cell death beneﬁts from
the generation of 1O2. Furthermore, the 1O2 production of FCNVs
and Ce6 were measured by using electron spin resonance (ESR)
spectroscopy under the same dose of Ce6. As shown in Fig. S13y, the
1O2 production of FCNVs is higher than that of free Ce6 under the
same conditions, which may beneﬁt from the stronger absorption
of FCNVs at ca. 660 nm [16,40].
To the PDT effect of FCNVs, the in vitro viability assay of
A549 cells were selected as model. As shown in Fig. 3e, negligible
cytotoxicity is observed when A549 cells are incubated with FCNVs
at a series of gradient concentrations up to 0.2 mgmL1 in the dark,
indicating the favorable biocompatibility of FCNVs. In contrast, the
cell viabilities decrease signiﬁcantly with increasing FCNVs con-
centration upon 660 nm laser irradiation at power density of
20 mW cm2 for 10 min, and 95% inhibitory effect is achieved at
0.2 mgmL1 of FCNVs. In order to show the excellent PDTefﬁciency
of FCNVs, we compare the cell viabilities treated by FCNVswith that
of free Ce6 (at an equiv. Ce6 dose of 0.1 mg mL1) or TFC70 alone
(0.1 mg mL1) under the same conditions (Fig. 3f). The results
indicate that FCNVs exhibited a much better PDT efﬁciency than
either free Ce6 or TFC70 alone. The reasons on one handmay ascribe
to the higher uptake of FCNVswith a high coupling efﬁciency of Ce6
by A549 cells than that of free Ce6, on the other hand, should
beneﬁt from the highly efﬁcient absorption of FCNVs at 660 nm
than that of free TFC70 [16,40]. Furthermore, human immortal
keratinocyte line (HaCaT) was used as a control to explore the
selectivity of FCNVs and Ce6. As shown in Fig. S14y, either FCNVs or
Ce6 shows a favorable lethality to A549 cells under laser irradiation,
which may contribute to the higher uptake of FCNVs or Ce6 to
cancer cells than normal cells (Fig. S15y) [20].
In addition, confocal images (Fig. S16y) were recorded to
investigate the dynamic process of cell death by observing the
bubble produced by the cells under light irradiation. At the same
time, red FL emitted from FCNVs could be detected in cytoplasm
which indicated that FCNVs were uptaken into cytoplasm of cells.
Several subcellular organelles were stained by related probes and
observed under confocal microscope to conﬁrm that the cells were
destructed after incubation with FCNVs followed by subsequent
Fig. 3. (a) Confocal FL images of cells incubated with free Ce6 (above), and FCNVs (bottom) at different periods of incubation time (0.5, 1, 3, 7, and 24 h) at an equiv. Ce6 dose of
0.1 mg mL1. (b) Quantitative evaluation of the cellular uptake of Ce6 and FCNVs was carried out by comparing the FL intensities of cellular lysates at different incubation time. (c)
Confocal images of DCFDA stained cells, and those subsequently treated with Ce6, and FCNVs at different irradiation time. (d) Time-dependent FL intensity of 1O2 production
detected by FL of DCFDA in A549 cells treated with Ce6, and FCNVs, respectively. Free DCFDA is used as control. (e) In vitro relative viabilities of A549 cells incubated with FCNVs at a
gradient of concentrations, with 660 nm laser irradiation (red) or in dark (black). (f) Relative viabilities of A549 cells incubated with either FCNVs, or free Ce6 (at an equiv. Ce6 dose
of 0.1 mg mL1) and TFC70 alone (0.1 mg mL1), respectively, with 660 nm laser irradiation (red) or in dark (black). (g) Confocal images before (left) and after 660 nm laser
irradiation (right). First line was stained with DiI and Hoechst 33258, second line was stained with MitoRed and Hoechst 33258, third line was stained with PI and Lyso. Each group
with two columns represents FL image and merged image, respectively.
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ﬁrst row were stained by DiI (cell membrane dye) and Hoechst
33258 (nucleus dye), from which we can see clearly that the cell
membrane was bubbling and the nuclei were stained with blue,
suggesting that the cells were dead. The second rowwas stained by
MitoRed tracker (mitochondrial dye) and Hoechst 33258, and the
third row was stained by Lyso tracker (lysosome dye) and PI (nu-
cleus dye). The compact mitochondria and lysosomes became
incomplete and nuclei were stained with red and blue respectively
after irradiation of 660 nm laser, indicating the subcellular organ-
elles were destroyed by 1O2 generated from FCNVs. In addition, two
short videos were recorded for observing the changes of membrane
(stained by DiI) and mitochondrial (stained by MitoRed) upon
660 nm laser irradiation in SI (MV), which clearly demonstrate the
above phenomenon.
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.biomaterials.2016.06.023
3.3. In vivo imaging and PDT
FL intensity of FCNVs in vivo was detected to evaluate the real-
time biodistribution. For FL imaging studies, the luciferase-
expressing breast cancer cell line (4T1-luc) was selected as thexenograft model and the tumor-bearing female Balb/c mice were
injected with FCNVs through the tail vein (10 mg kg1). As ex-
pected, the FL images with negligible interference by auto-
ﬂuorescence from biological tissues could be used to monitor the
biodistribution of FCNVs in vivo. As shown in Fig. 4a, a rapid tropism
biodistribution associated with FCNVs accumulation was detected
and the FL intensity of FCNVs in tumor signiﬁcantly increased to the
maximum after 4 h post-injection (top line). By contrast, the female
Balb/c mouse treated with free Ce6 showed negligible FL in tumor
site under the same conditions (bottom line), which is similar to the
previous reports [61,73]. A sharp contrast of FCNVs vs. Ce6 treated
mice could be seen from the chronologically statistical analysis of
the relative average FL intensity at tumor site, as shown in Fig. 4b,
further suggesting the signiﬁcantly higher accumulation of the
FCNVs than that of free Ce6 in tumor site. This result would facili-
tate the efﬁcient PDT subsequently.
To evaluate the tumor inhibition efﬁcacy of FCNVs under
660 nm irradiation in vivo, four groups (n ¼ 5) of 4T1-luc tumor-
bearing female Balb/c mice were used in our experiments. Under
the guidance of FL imaging, the PDT treatmentwas conducted at 4 h
post i.v. injection. The mice in the PDT treatment groups were
intravenously injected with FCNVs (10 mg kg1) and then irradi-
ated with 660 nm laser at power density of 100 mW cm2 for
Fig. 4. (a) In vivo FL images of tumor-bearing mice at different time points after treatment with FCNVs (above) and Ce6 (bottom), respectively. (b) Relative FL intensity from tumor
site at different time points for different treatments. (c) The relative tumor volumes were normalized to their initial sizes for three groups after different treatments. (d) The relative
body weights of the Balb/c mice increased continuously after different treatments. Error bars indicate standard deviations; n ¼ 5. (e) Bioluminescence images of before (left) and
after treatment for 15 days (right). (f) H&E stained images of tumors under different PDT treatment.
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not irradiated with laser, and mice treated with saline solution and
subjected to laser irradiation were selected as control groups. The
tumor sizes and weights of mice were monitored every second day.
As shown in Fig. 4c, only the tumor of the mice treated with FCNVs
and subsequently irradiated with 660 nm laser became black and
scabby after 7 days treatment (Fig. S17y) and ablated after 15 days
treatment, while the tumors in other three control groups
continued growing along with time. In addition, body weight as an
important parameter to roughly evaluate the toxicity of nano-
medicine is monitored. As shown in Fig. 4d, no abnormal changes
were found for all groups, indicating there is no obvious acute
toxicity. The representative bioluminescence images of mice
injected with FCNVs and subsequently exposed to 660 nm irradi-
ation (Fig. 4e) were collected. The result reveals that the biolumi-
nescence of experimental group nearly disappeared comparedwith
saline-treated mice, which suggested that the tumor is effectively
destroyed. Furthermore, H&E staining image of the tumor after PDTtreatment shows obvious damage (Fig. 4f).3.4. Biodistribution and clearance of FCNVs
To study whether or not the FCNVs can be cleared out from the
body, 4T1-luc bearing Balb/c mice were sacriﬁced post-injection at
1 h, 4 h, 24 h, 2 d, 7 d, 15 d, and 20 d, respectively. Major organs
(heart, liver, spleen, lung, kidneys, and muscle) and tumors were
excised and imaged more accurately to evaluate the FL intensities
within tissues. Mice injected with Ce6 were used as controls.
Notably, strong FL from tumor, liver and kidney was detected,
whereas negligible FL was observed in spleen, lung, muscle and
heart, suggesting the FCNVs accumulate preferentially in former
tissues, as shown in Fig. 5a and b. The average FL intensity of FCNVs
accumulated in the tumor and organs areas quickly increases
within 1e4 h post-injection, and decreases at 24 h. At 20 days post-
injection, the FL decreases to undetectable level, whichmay excrete
through the feces and urine due to their preferential accumulation
Fig. 5. (a) Ex vivo FL images of tumor and major organs after different time points post-injection of FCNVs. (b) Relative FL intensity of tumor and major organs after different time
points post-injection of FCNVs. Inset is the measurement of half-life time (t1/2) of FCNVs in tumor. (c) Ex vivo FL images of tumor and major organs after different time points post-
injection of Ce6. (d) Relative FL intensity of tumor and major organs after different time points post-injection of Ce6. Inset is the measurement of half-life time (t1/2) of Ce6 in tumor.
(e) Biodistribution (%ID per g) at various time points post i.v. administration of 131I-FCNVs. Inset is the measurement of half-life time (t1/2) of FCNVs in bloodstream.
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mice injected with free Ce6 mainly accumulated in liver and kid-
neys, and only a little accumulated in tumor site (Fig. 5c and d),
which may ascribe to the low solubility and aggregating in water.
Further investigation revealed the half-life (t1/2) of FCNVs and Ce6
in tumor was 73.6 h and 13.2 h (Inset of Fig. 5b and d), respectively,
indicating the blood circulation time of FCNVs was signiﬁcantly
longer than that of free Ce6 [75]. The biodistribution of FCNVs
in vivo is difﬁcult to be quantiﬁed accurately from FL measurement
due to the tissue autoﬂuorescence [76]. Therefore, the radiolabeling
strategy [77e79] is demonstrated by incorporating radionuclides(131I) into FCNVs, and the uptake (%ID per g) values of 131I-FCNVs in
bloodstream and major organs collected from Balb/c mice at
different time points post tail vein injection (1 h, 4 h, 24 h, 2 d, 7 d,
15 d, and 20 d; n ¼ 5 per time point) are plotted (Fig. 5e). The
biodistribution and clearance of FCNVs in major organs and tumor
are comparable to the FL measurement. At 20 days post-injection,
the radio activity decreases to undetectable level, further con-
ﬁrming the complete clearance of FCNVs from the body. The half-
life time of 131I-FCNVs in bloodstream is 9.68 h (Insert of Fig. 5e),
which is three times larger than that of previously reported free Ce6
(3.6 h) [74], due to the presence of OEG and the nanovesicular
M. Guan et al. / Biomaterials 103 (2016) 75e8584structure of FCNVs [56,80,81]. H&E staining images of major organs
are presented in Fig. S18y, the results don't show any obvious le-
sions, indicating FCNVs don't have signiﬁcant toxicity to organism.
The above results suggest that the FCNVs indeed could be excreted
by liver and kidney with long time blood circulation and hold great
promise for medical applications in cancer therapy.
4. Conclusion
In summary, we developed a novel phototheranostic platform
based on FCNVs. Combining the respective advantages of fullerene
and Ce6, the obtained FCNVs have the following characteristics: (i)
a high Ce6 loading efﬁciency (up to ~57 wt%); (ii) efﬁcient ab-
sorption in NIR region; (iii) enhanced cellular uptake efﬁciency
in vitro as well as in vivo; (iv) simultaneous enhanced tumor im-
aging and PDT; (v) good biocompatibility and total clearance out
from body. These unique properties suggest that as-prepared
FCNVs can be used as new NIR-triggered phototheranostic agents
for enhanced FL imaging guided PDT treatment. This work may
pave the way for highly efﬁcient phototheranostic applications
based on FCNVs.
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